Tirzepatide
A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).
In plain English
Tirzepatide is a single peptide that activates two gut-hormone receptors at once: GLP-1 and GIP. In the SURMOUNT trial program, adults with obesity lost an average of ~20% of body weight over 72 weeks on the highest dose — the largest sustained weight loss seen with any non-surgical drug. Tirzepatide also produced large HbA1c reductions in type 2 diabetes (SURPASS program). It is FDA-approved as Mounjaro (T2D) and Zepbound (chronic weight management; obstructive sleep apnea in people with obesity added in 2024). Side effects are dominated by gastrointestinal symptoms during dose escalation.
What it is
Tirzepatide is a 39-amino-acid synthetic peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.
Mechanism (summary)
Simultaneous activation of GIP and GLP-1 receptors produces additive effects on glucose-dependent insulin secretion, appetite suppression, gastric emptying, and energy expenditure.
Why people research it
- Type 2 diabetes glycemic control
- Chronic weight management
- Obstructive sleep apnea in adults with obesity
- Investigational MASH and heart failure with preserved ejection fraction
Human evidence
SURPASS (T2D) and SURMOUNT (obesity) programs together enrolled tens of thousands. SURMOUNT-1 showed average weight loss of ~20.9% at 15 mg over 72 weeks vs. ~3.1% on placebo. SURMOUNT-OSA showed reductions in apnea-hypopnea index.
Animal / lab evidence
Preclinical work supported the dual-receptor design and showed greater effects on body weight and glucose than GLP-1 mono-agonism.
Key studies
Each summary explains the design, what was found, and what it doesn't prove.
Adults with obesity lost about a fifth of their body weight on tirzepatide over 72 weeks, vs. ~3% on placebo.
In a head-to-head trial in type 2 diabetes, tirzepatide lowered blood sugar and weight more than semaglutide 1 mg.
Adults with obesity and sleep apnea had far fewer breathing interruptions per hour of sleep on tirzepatide than on placebo.
History
Developed by Eli Lilly. Mounjaro (T2D) approved 2022; Zepbound (chronic weight management) approved 2023; OSA indication added 2024.
PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.
Related peptides
A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy).
An investigational triple GLP-1 / GIP / glucagon receptor agonist showing the largest weight-loss effects yet seen in mid-stage trials.
A 16-amino-acid C-terminal fragment of human growth hormone studied for fat metabolism, with disappointing weight-loss outcomes in humans.